Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Stage III Breast Cancer AJCC V7
Interventions: OTHER: epirubicin/docetaxel sequential
Sponsor: University of Bergen
Collaborators: Haukeland University Hospital